First-in-human test of an anti-PVRIG drug for advanced cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced or metastatic solid cancer that cannot be removed by surgery, and it has worsened after standard treatment or you can’t tolerate standard treatment (or no effective standard option exists).
- You have at least one measurable cancer spot on scans.
- You are generally strong enough for treatment (ECOG performance status 0 to 2) and expected to live at least 3 months.
- Your heart, lungs, and other organs/labs must be adequate for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This early-stage trial tests a new experimental drug (MST-0312) in people with solid tumors like lung cancer, melanoma, bladder cancer, colorectal cancer, or triple-negative breast cancer. The goal is to find safe doses and see how well it works, either by itself or paired with other treatments.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
This Phase 1 trial tests how safe PMC-309 is and how the drug behaves in the body (blood levels) in people with advanced or metastatic solid tumors. Because it’s an early study, the main goal is to find safe dosing and gather information that could guide future treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.